However, the presence of additional somatic mutation in different genes, such as SRSF2, ASXL1, RUNX1, EZH2, and loss of function of SETD2, may impact the disease course, especially in the aggressive forms of SM, and may drive a personalized therapeutic approach [8,9,10]. Here, RUNX1 is linked to systemic mastocytosis.